Targeted kinase inhibitors (TKI) are among the most successful targeted cancer therapies. However, TKIs simultaneously inhibit several human protein kinases, often causing undesirable off-target toxicity. Together with his research group at Berlin Institute of Health, the renowned chemist and biophysicist John Chodera works on increasing the effectiveness of TKIs, making an important contribution to the treatment of cancer. Chodera, who has previously worked at University of California, Berkeley, and Stanford University, is now an Associate Professor for Physiology, Biophysics and Systems Biology at Memorial Sloan-Kettering Cancer Center in New York.
More about John Chodera
In the article "Logic Lights" from the series "Elephants & Butterflies," John Chodera describes the function of kinases, which organize cell division in the body. The aim of his research is to accelerate the development of cancer medicines.
Photo: John Chodera
Short Vita
Since 2019
Einstein Visiting Fellow at Berlin Institute of Health
Since 2018
Associate Professor of Physiology, Biophysics and Systems Biology atMemorial Sloan Kettering Cancer Center in New York, USA
2008 - 2012
Independent Distinguished Postdoctoral Fellow at California Institute for Quantitative Biosciences (QB3), University of California, Berkeley, USA
2006 - 2008
Postdoctoral researcher at Department of Chemistry, Stanford University, USA
Einstein Questionnaire
"Please close your eyes and think about your research project. What do you see at first?" All questions & answers by John Codera
Follow us on